HRP20250885T1 - Spojevi kondenziranog tricikličkog piridazinona korisni za liječenje ortomiksovirusnih infekcija - Google Patents

Spojevi kondenziranog tricikličkog piridazinona korisni za liječenje ortomiksovirusnih infekcija

Info

Publication number
HRP20250885T1
HRP20250885T1 HRP20250885TT HRP20250885T HRP20250885T1 HR P20250885 T1 HRP20250885 T1 HR P20250885T1 HR P20250885T T HRP20250885T T HR P20250885TT HR P20250885 T HRP20250885 T HR P20250885T HR P20250885 T1 HRP20250885 T1 HR P20250885T1
Authority
HR
Croatia
Prior art keywords
image
pharmaceutically acceptable
acceptable salt
compound according
compounds useful
Prior art date
Application number
HRP20250885TT
Other languages
English (en)
Croatian (hr)
Inventor
Rama Jain
Dennis Christofer KOESTER
James R. MANNING
Vanessa Marx
Daniel Poon
James Clifford Sutton
Benjamin R. TAFT
Lifeng Wan
Aregahegn Yifru
Qian Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20250885T1 publication Critical patent/HRP20250885T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20250885TT 2016-08-29 2017-08-25 Spojevi kondenziranog tricikličkog piridazinona korisni za liječenje ortomiksovirusnih infekcija HRP20250885T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380712P 2016-08-29 2016-08-29
EP23217305.4A EP4356969B1 (en) 2016-08-29 2017-08-25 Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections

Publications (1)

Publication Number Publication Date
HRP20250885T1 true HRP20250885T1 (hr) 2025-09-26

Family

ID=59923494

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250885TT HRP20250885T1 (hr) 2016-08-29 2017-08-25 Spojevi kondenziranog tricikličkog piridazinona korisni za liječenje ortomiksovirusnih infekcija

Country Status (20)

Country Link
US (4) US11098051B2 (cg-RX-API-DMAC7.html)
EP (4) EP4356969B1 (cg-RX-API-DMAC7.html)
JP (3) JP7221861B2 (cg-RX-API-DMAC7.html)
CN (2) CN109863151B (cg-RX-API-DMAC7.html)
AR (1) AR109438A1 (cg-RX-API-DMAC7.html)
CA (1) CA3035302A1 (cg-RX-API-DMAC7.html)
DK (1) DK4356969T3 (cg-RX-API-DMAC7.html)
ES (3) ES2974494T3 (cg-RX-API-DMAC7.html)
FI (1) FI4356969T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250885T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072776T2 (cg-RX-API-DMAC7.html)
JO (1) JOP20170169A1 (cg-RX-API-DMAC7.html)
LT (1) LT4356969T (cg-RX-API-DMAC7.html)
MX (1) MX383124B (cg-RX-API-DMAC7.html)
PL (3) PL4356969T3 (cg-RX-API-DMAC7.html)
PT (3) PT3504214T (cg-RX-API-DMAC7.html)
SI (3) SI3504214T1 (cg-RX-API-DMAC7.html)
TW (3) TWI869757B (cg-RX-API-DMAC7.html)
UY (2) UY37378A (cg-RX-API-DMAC7.html)
WO (1) WO2018042303A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764904B (zh) * 2013-09-12 2020-02-11 詹森生物制药有限公司 氮杂-吡啶酮化合物及其用途
HK1254961A1 (en) 2015-12-15 2019-08-02 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
US10759814B2 (en) 2016-08-10 2020-09-01 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
CN111848615B (zh) 2018-01-17 2022-05-17 江西彩石医药科技有限公司 吡啶酮衍生物及包含其的抗流感病毒药物组合物
HUE069183T2 (hu) * 2018-02-28 2025-02-28 Novartis Ag 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére
CN108440564B (zh) * 2018-04-11 2019-08-06 安帝康(无锡)生物科技有限公司 被取代的多环氨基甲酰基吡啶酮衍生物及其前药
TW202035424A (zh) * 2018-10-10 2020-10-01 美商健生生物製藥公司 大環流感內切核酸酶抑制劑
CN111909174B (zh) 2019-05-08 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物的晶型及制备方法和应用
CN115135646B (zh) * 2019-12-23 2024-05-17 石家庄迪斯凯威医药科技有限公司 取代的多环化合物及其药物组合物和用途
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
WO2022105669A1 (zh) * 2020-11-17 2022-05-27 南京明德新药研发有限公司 含Se大环类化合物
EP4707279A1 (en) * 2023-05-02 2026-03-11 Albius Sciences Beta Pte. Ltd. Substituted tricyclic heterocyclic compound as pharmaceutical for treatment or prevention of covid-19

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2225112A (en) 1938-07-09 1940-12-17 Wright Aeronautical Corp Air cleaner
GB8501542D0 (en) 1985-01-22 1985-02-20 Erba Farmitalia 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives
AUPM354694A0 (en) 1994-01-27 1994-02-17 Biota Scientific Management Pty Ltd Chemical compounds
ATE530520T1 (de) 2001-08-10 2011-11-15 Shionogi & Co Antivirales mittel
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
AU2005221864A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
FR2901795A1 (fr) 2006-05-30 2007-12-07 Fourtillan Snc Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique
EA019520B1 (ru) 2008-10-31 2014-04-30 Сионоги Энд Ко., Лтд. Цефалоспорины, содержащие катехольную группу
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8835461B2 (en) 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
JP5737691B2 (ja) * 2009-06-15 2015-06-17 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体
CN102762568A (zh) 2009-12-23 2012-10-31 伊兰药品公司 作为polo样激酶的抑制剂的蝶啶酮
TW201201813A (en) 2010-03-31 2012-01-16 Arqule Inc Substituted benzo-pyrido-triazolo-diazepine compounds
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
LT2620436T (lt) 2010-09-24 2018-08-10 Shionogi & Co., Ltd. Pakeistojo policiklinio karbamoilpiridono darinio provaistas
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
AU2012321762A1 (en) * 2011-10-12 2014-04-17 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
US9278996B2 (en) 2012-09-20 2016-03-08 Celltrion, Inc. Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same
EA201591291A1 (ru) 2013-01-08 2015-12-30 Савира Фармасьютикалз Гмбх Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
CA2921294C (en) 2013-08-21 2023-05-16 Alios Biopharma, Inc. Antiviral compounds
CN105530946A (zh) 2013-09-11 2016-04-27 南加利福尼亚大学 具有高度表达的fas配体的干细胞组合物
CN105764904B (zh) 2013-09-12 2020-02-11 詹森生物制药有限公司 氮杂-吡啶酮化合物及其用途
AU2014318837B2 (en) 2013-09-12 2019-05-30 Janssen Biopharma, Inc. Pyridazinone compounds and uses thereof
CA2953862A1 (en) 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
WO2016145103A1 (en) 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
WO2017156407A1 (en) 2016-03-10 2017-09-14 Alios Biopharma, Inc. Method of preparing aza-pyridone compounds
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
US10759814B2 (en) 2016-08-10 2020-09-01 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
JP2019059697A (ja) * 2017-09-28 2019-04-18 塩野義製薬株式会社 置換された多環性ピリダジン誘導体およびそのプロドラッグ
CN110041327B (zh) 2018-01-17 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN111848615B (zh) 2018-01-17 2022-05-17 江西彩石医药科技有限公司 吡啶酮衍生物及包含其的抗流感病毒药物组合物
KR20200126973A (ko) 2018-02-28 2020-11-09 니뽄 다바코 산교 가부시키가이샤 4-메틸디히드로피리미디논 화합물 및 그의 의약 용도
PE20211456A1 (es) 2018-02-28 2021-08-05 Hoffmann La Roche Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado
CN111741948B (zh) 2018-02-28 2023-11-10 日本烟草产业株式会社 饱和环稠合的二氢嘧啶酮或二氢三嗪酮化合物及其药物用途
HUE069183T2 (hu) 2018-02-28 2025-02-28 Novartis Ag 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére

Also Published As

Publication number Publication date
PT4356969T (pt) 2025-10-02
LT4356969T (lt) 2025-09-10
ES3042460T3 (en) 2025-11-20
EP4356969B1 (en) 2025-07-09
HUE072776T2 (hu) 2025-12-28
US20220041610A1 (en) 2022-02-10
JP2023027102A (ja) 2023-03-01
US11912715B2 (en) 2024-02-27
US20250011334A1 (en) 2025-01-09
JP7221861B2 (ja) 2023-02-14
US11098051B2 (en) 2021-08-24
TWI803467B (zh) 2023-06-01
MX2019002438A (es) 2019-07-08
TW201811800A (zh) 2018-04-01
ES2859510T3 (es) 2021-10-04
JOP20170169A1 (ar) 2019-01-30
SI3504214T1 (sl) 2021-04-30
UY40872A (es) 2024-09-13
UY37378A (es) 2018-03-23
EP4640279A2 (en) 2025-10-29
EP4640279A3 (en) 2025-12-24
TW202342482A (zh) 2023-11-01
DK4356969T3 (da) 2025-08-18
US20200123167A1 (en) 2020-04-23
PL3848372T3 (pl) 2024-04-22
EP3504214B1 (en) 2020-12-02
AR109438A1 (es) 2018-11-28
EP3504214A1 (en) 2019-07-03
US20180057501A1 (en) 2018-03-01
TW202517646A (zh) 2025-05-01
EP4356969A2 (en) 2024-04-24
CN109863151A (zh) 2019-06-07
FI4356969T3 (fi) 2025-08-15
PL4356969T3 (pl) 2025-10-20
CN113683614A (zh) 2021-11-23
PL3504214T3 (pl) 2021-07-19
JP2025081322A (ja) 2025-05-27
WO2018042303A1 (en) 2018-03-08
PT3504214T (pt) 2021-03-04
EP3848372A1 (en) 2021-07-14
US10160764B2 (en) 2018-12-25
SI4356969T1 (sl) 2025-10-30
CN113683614B (zh) 2024-11-08
TWI869757B (zh) 2025-01-11
JP2019532033A (ja) 2019-11-07
EP4356969A3 (en) 2024-05-22
EP3848372B1 (en) 2023-12-20
SI3848372T1 (sl) 2024-04-30
CA3035302A1 (en) 2018-03-08
ES2974494T3 (es) 2024-06-27
CN109863151B (zh) 2021-09-10
PT3848372T (pt) 2024-03-22
MX383124B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20171807T1 (hr) Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija
HRP20230274T1 (hr) Kemijski spojevi
HRP20170654T1 (hr) Makrociklički deaza-purinoni za liječenje virusnih infekcija
HRP20211224T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
HRP20231018T1 (hr) Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije
HRP20210241T1 (hr) Derivat policikličkog piridona protiv gripe i njegov predlijek
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
HRP20161125T1 (hr) Makrociklički purini za liječenje virusnih infekcija
HRP20180791T1 (hr) Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20220920T1 (hr) Pirolo[1,2-f][1,2,4]triazini koji su korisni za liječenje infekcija respiratornim sincicijalnim virusom
HRP20210942T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20201023T1 (hr) Dioksilan analozi uridina za liječenje raka
HRP20171808T1 (hr) Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20211762T1 (hr) Derivati benzoksaborola za liječenje bakterijskih infekcija
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
HRP20241221T1 (hr) POLICIKLIČNI KARBAMOILPIRIDONSKI DERIVATI ZA LIJEČENJE HIV-a
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
EA201491525A1 (ru) Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
HRP20241558T1 (hr) Dvojni inhibitori magl i faah
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina